Nominations for the 2014 award are now closed.
View the list of all prior lectureship recipients.
The AACR Princess Takamatsu Memorial Lectureship was established and first presented in 2007 in honor of the late Princess Takamatsu of Japan. During her extraordinary life, Her Imperial Highness Princess Takamatsu expended tremendous efforts toward the public and humanitarian cause of the eradication of cancer. She is regarded as an honored and respected figure in Japan, the United States, and within the international cancer research community as a whole.
Learn more about Princess Takamatsu.
This lectureship will recognize an individual scientist whose novel and significant work has had or may have a far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and who embodies the dedication of the Princess to multinational collaborations. The recipient of the Eight Annual Lectureship will present a major, 50-minute lecture during the AACR Annual Meeting 2014 in San Diego, CA, USA (April 5-9, 2014).
The lecturer will receive an unrestricted honorarium of US $10,000, support for the winner and a guest to attend the AACR Annual Meeting, and a commemorative item serving as tangible witness to the singular honor of his/her selection.
- Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government.
- The lectureship will be presented to an individual investigator.
- Institutions or organizations are not eligible for the lectureship.
Nomination Procedure and Instructions
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Nomination materials to be submitted are:
1) Nomination letter which must:
- be addressed to the Selection Committee; be written in English; and not exceed 1,000 words;
- specify the AACR award for which the candidate is being nominated;
- contain a concise description of the candidate's novel and significant work in cancer research and dedication to multinational collaborations;
- contain publications supporting these contributions directly referenced within the letter (if applicable); and
- be signed by the nominator(s).
2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications. Word and PDF files will be accepted.
3) Summary Statement. A statement, no more than 50 words, summarizing the candidate's research accomplishments for which he or she is being nominated.
Nominations must be emailed to firstname.lastname@example.org by 4:00 p.m. United States Eastern Time on Thursday, September 19, 2013. Paper nominations will not be accepted. Full nomination instructions and program guidelines are available through the link below.
Program Guidelines and Nomination Instructions. Download the Adobe Acrobat Reader here.
Candidates will be considered by a Selection Committee of international cancer leaders appointed by the president of the AACR. Selection of the lecturer will be made on the basis of the novel and significant work, its far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and his or her embodiment of the dedication of the Princess to multinational collaborations. No regard will be given to age, race, gender, nationality, geographic location or religious or political views. After careful deliberations by the committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision.
Generously supported by the Princess Takamatsu Cancer Research Fund (Japan).
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
Seventh Annual Award Recipient
Carlo M. Croce, M.D.
Human Cancer Genetics
The Ohio State University Comprehensive Cancer Center
Dr. Croce delivered his award lecture titled Causes and Consequences of MicroRNA Dysregulation in Cancer
, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Monday, April 8, 2013. Visit the AACR Annual Meeting 2013
page for more information on the Annual Meeting.
Dr. Carlo M. Croce is honored for his seminal contributions to cancer genetics. Dr. Croce was the first to show that cancer is a genetic disease resulting from somatic genetic alterations, based on his study of Burkett lymphoma. Under his guidance, with the use of gene cloning technology, Dr. Yoshihide Tsujimoto cloned the BCL1 locus and then the gene, which Dr. Croce named BCL2, responsible for follicular lymphoma. His findings and innovative approaches constitute the intellectual basis for the conceptual development of targeted therapy.
During the past twenty years, Dr. Croce has used this approach to isolate and characterize many additional oncogenes and tumor suppressor genes. More recently, in studying the pathogenesis of chronic lymphocytic leukemia, he made an additional transformational discovery. Dr. Croce found that the loss of two microRNA genes, miR-15a and miR-16-1, is involved in the pathogenesis of this disease, thus demonstrating that a family of genes that do not encode for proteins is involved in cancer pathogenesis. Dr. Croce extended this seminal observation to show that microRNA dysregulation is common to all human cancers, a significant discovery providing new approaches for cancer diagnostics, prognostics and treatment.
Dr. Croce's research is world-renowned and he has been acknowledged as a leading expert in his field through many prestigious honors and awards. He is an elected member of the National Academy of Sciences, USA, the Institute of Medicine, the American Association of Physicians, and a member of the American Academy of Arts and Sciences. He has received two prestigious AACR Awards: the 2006 AACR G.H.A. Clowes Memorial Award and the 1999 AACR-Pezcoller International Award for Cancer Research. Additional Awards include The Henry M. Stratton Medal from the American Society of Hematology, the Albert Szent-Gyorgyi Prize for Progress in Cancer Research, and the 2003 Italian Gold Medal for Public Health.